CBS 2019
CBSMD教育中心
中 文

推荐文献

Abstract

Recommended Article

Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events in the ODYSSEY OUTCOMES Trial Optimal medical therapy improves clinical outcomes in patients undergoing revascularization with percutaneous coronary intervention or coronary artery bypass grafting: insights from the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial at the 5-year follow-up Limitations of Repeat Revascularization as an Outcome Measure Healthy Behavior, Risk Factor Control, and Survival in the COURAGE Trial Significantly less inappropriate shocks in ischemic patients compared to non-ischemic patients: The S-ICD experience of a high volume single-center Potential protective mechanisms of green tea polyphenol EGCG against COVID-19 Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials Poor R-wave progression as a predictor of sudden cardiac death in general population and subjects with coronary artery disease

Original Research2018 Aug 27.

JOURNAL:N Engl J Med. Article Link

Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation

Obadia JF, Messika-Zeitoun D, MITRA-FR Investigators et al. Keywords: chronic heart failure; reduced left ventricular ejection fraction; severe secondary mitral-valve regurgitation; percutaneous mitral-valve repair;clinical outcome

FULL TEXT PDF